Conference Reports for NATAP

The Liver Meeting Washington DC October 2017 Back

Evaluation of an early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C patients treated with All-Oral DAAs       - propensity score-matched analysis of a prospective database -   AASLD: The incidence of hepatocellular carcinoma is not increased after DAA therapy - (11/13/17)   AASLD: Low Rates of De Novo or Recurrent Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct-Acting Antivirals (DAAs): A Single-Center Experience - (11/16/17)   Reported by Jules Levin AASLD Annual Meeting 2017, Washington, DC, USA, October 20-24   Mina Nakagawa1)2) Yasuhiro Asahina1)3) ,Hiroko Nagata1) and Mamoru Watanabe1) 1) Department of Gastroenterology and Hepatology 2) Institute of Education 3) Department of Liver Disease Control Tokyo Medical and Dental University, Tokyo, Japan